Compare BNGO & GDTC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BNGO | GDTC |
|---|---|---|
| Founded | 2003 | 2018 |
| Country | United States | Singapore |
| Employees | N/A | N/A |
| Industry | Biotechnology: Laboratory Analytical Instruments | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 11.6M | 12.4M |
| IPO Year | 2018 | 2021 |
| Metric | BNGO | GDTC |
|---|---|---|
| Price | $1.16 | $1.03 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 3 | 0 |
| Target Price | ★ $6.33 | N/A |
| AVG Volume (30 Days) | ★ 257.0K | 11.5K |
| Earning Date | 03-23-2026 | 04-24-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 94.50 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $12,000,735.00 | N/A |
| Revenue This Year | $25.49 | $5.37 |
| Revenue Next Year | $48.03 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 26.26 | N/A |
| 52 Week Low | $1.06 | $0.73 |
| 52 Week High | $5.50 | $3.68 |
| Indicator | BNGO | GDTC |
|---|---|---|
| Relative Strength Index (RSI) | 47.01 | 45.91 |
| Support Level | $1.07 | $0.96 |
| Resistance Level | $1.18 | $1.11 |
| Average True Range (ATR) | 0.07 | 0.06 |
| MACD | 0.01 | 0.00 |
| Stochastic Oscillator | 13.51 | 45.13 |
Bionano Genomics Inc is a life sciences instrumentation company in the genome analysis space. It is engaged in the development and marketing of the Saphyr system, a platform for ultra-sensitive and ultra-specific structural variation detection that enables researchers and clinicians to accelerate the search for new diagnostics and therapeutic targets and to streamline the study of changes in chromosomes. Geographically, it operates in the Americas, EMEA, and Asia Pacific, of which the EMEA region generates the majority of its revenue. It generates product revenue from sales of its OGM and Ionic Purification systems and consumables, which include its instruments and their VIA software.
CytoMed Therapeutics Ltd is a pre-clinical biopharmaceutical company focused on harnessing its proprietary technologies to create novel cell-based immunotherapies for the treatment of human cancers. The company's segment include: the business of innate immune cell-based immunotherapy, pluripotent stem cell-based therapy and undertaking the research and development of immune cell and stem cell-based therapy; and the business of processing and banking of cells including cord blood stem cells, research and development on cord blood derived cell-based therapy. Geographically, the company operates in Singapore and Malaysia which is the majority revenue generator.